Apolipoprotein M - a new biomarker in sepsis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Apolipoprotein M - a new biomarker in sepsis. / Christoffersen, Christina; Nielsen, Lars Bo.

I: Critical Care (Online Edition), Bind 16, Nr. 3, 2012, s. 126.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Christoffersen, C & Nielsen, LB 2012, 'Apolipoprotein M - a new biomarker in sepsis', Critical Care (Online Edition), bind 16, nr. 3, s. 126. https://doi.org/10.1186/cc11320

APA

Christoffersen, C., & Nielsen, L. B. (2012). Apolipoprotein M - a new biomarker in sepsis. Critical Care (Online Edition), 16(3), 126. https://doi.org/10.1186/cc11320

Vancouver

Christoffersen C, Nielsen LB. Apolipoprotein M - a new biomarker in sepsis. Critical Care (Online Edition). 2012;16(3):126. https://doi.org/10.1186/cc11320

Author

Christoffersen, Christina ; Nielsen, Lars Bo. / Apolipoprotein M - a new biomarker in sepsis. I: Critical Care (Online Edition). 2012 ; Bind 16, Nr. 3. s. 126.

Bibtex

@article{1b615cf43a8f4f2abe794b4362f551d0,
title = "Apolipoprotein M - a new biomarker in sepsis",
abstract = "ABSTRACT: Sepsis is one of the leading causes of mortality in non-cardiac intensive care units, and the need for markers of progression and severity are high. Also, treatment of sepsis is highly debated and potential new targets of treatment are of great interest. In the previous issue of Critical Care Kumaraswamy and colleagues have investigated whether plasma apolipoprotein M (apoM) is affected during different grades of sepsis, septic shock and systemic inflammatory response syndrome. Interestingly, plasma apoM was significantly decreased in all groups of patients with a relationship to severity of disease. This identifies apoM as a potential new biomarker in sepsis. It also underscores the possibility that altered high-density lipoprotein in sepsis patients can affect the course of disease. Thus, since apoM is the carrier of Sphingosine-1-P (S1P), a molecule with great influence on vascular barrier function, the study presented raises the interest and relevance for further studies of apoM and S1P in relation to sepsis and inflammation.",
author = "Christina Christoffersen and Nielsen, {Lars Bo}",
year = "2012",
doi = "10.1186/cc11320",
language = "English",
volume = "16",
pages = "126",
journal = "Critical Care",
issn = "1364-8535",
publisher = "BioMed Central Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Apolipoprotein M - a new biomarker in sepsis

AU - Christoffersen, Christina

AU - Nielsen, Lars Bo

PY - 2012

Y1 - 2012

N2 - ABSTRACT: Sepsis is one of the leading causes of mortality in non-cardiac intensive care units, and the need for markers of progression and severity are high. Also, treatment of sepsis is highly debated and potential new targets of treatment are of great interest. In the previous issue of Critical Care Kumaraswamy and colleagues have investigated whether plasma apolipoprotein M (apoM) is affected during different grades of sepsis, septic shock and systemic inflammatory response syndrome. Interestingly, plasma apoM was significantly decreased in all groups of patients with a relationship to severity of disease. This identifies apoM as a potential new biomarker in sepsis. It also underscores the possibility that altered high-density lipoprotein in sepsis patients can affect the course of disease. Thus, since apoM is the carrier of Sphingosine-1-P (S1P), a molecule with great influence on vascular barrier function, the study presented raises the interest and relevance for further studies of apoM and S1P in relation to sepsis and inflammation.

AB - ABSTRACT: Sepsis is one of the leading causes of mortality in non-cardiac intensive care units, and the need for markers of progression and severity are high. Also, treatment of sepsis is highly debated and potential new targets of treatment are of great interest. In the previous issue of Critical Care Kumaraswamy and colleagues have investigated whether plasma apolipoprotein M (apoM) is affected during different grades of sepsis, septic shock and systemic inflammatory response syndrome. Interestingly, plasma apoM was significantly decreased in all groups of patients with a relationship to severity of disease. This identifies apoM as a potential new biomarker in sepsis. It also underscores the possibility that altered high-density lipoprotein in sepsis patients can affect the course of disease. Thus, since apoM is the carrier of Sphingosine-1-P (S1P), a molecule with great influence on vascular barrier function, the study presented raises the interest and relevance for further studies of apoM and S1P in relation to sepsis and inflammation.

U2 - 10.1186/cc11320

DO - 10.1186/cc11320

M3 - Journal article

C2 - 22587809

VL - 16

SP - 126

JO - Critical Care

JF - Critical Care

SN - 1364-8535

IS - 3

ER -

ID: 38431719